CNBX Pharmaceuticals (CNBX)

Executive Summary

CNBX Pharmaceuticals is a private US biopharmaceutical company pioneering cannabinoid-based therapeutics for oncology and neuropsychiatry, with a lead candidate targeting colorectal cancer. Founded in 2018, the company leverages proprietary high-throughput screening and bioinformatics to identify and formulate novel cannabinoid-molecule drugs with antitumor effects. Its valuation of approximately $367,000 underscores its early-stage status and limited capital resources. The company trades under ticker CNBX and is headquartered in New York. Despite promising preclinical data, CNBX faces significant development risks, including regulatory hurdles, clinical trial uncertainties, and intense competition in the cannabinoid therapeutics space. The company has no marketed products or FDA approvals. Near-term value hinges on advancing its pipeline toward clinical trials, securing partnerships, or obtaining financing. Given the early stage and minimal market traction, the outlook is speculative.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase I Clinical Trial for Lead Colorectal Cancer Candidate20% success
• Q4 2026Presentation of Preclinical Data at a Major Oncology Conference40% success
• TBDPotential Licensing or Collaboration Agreement10% success